Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GREVAX H5N1
- Development stage
- Unknown
- Lead developer
- Greffex
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GREVAX H5N1 is an adenoviral vector-based vaccine developed by Greffex in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) for the prevention of H5N1 avian influenza. The vaccine utilizes the proprietary Clean Ad platform, which features a fully deleted, helper-independent adenoviral vector. By removing all viral genes (E1, E2, E3, and E4), the platform minimizes anti-vector immunity and provides significant genetic space for the H5N1 hemagglutinin (HA) antigen. This approach is designed to induce both robust neutralizing antibody titers and cellular immune responses. The vaccine is intended for rapid production in response to pandemic threats and has been evaluated in Phase 1/2 clinical trials.
- Other names
- H5N1 vaccine-NIH-vaccine-gene transfer vector-adenoviral vector-Avian Influenza (H5N1)Greffex H5N1 vaccineClean Ad H5N1 vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on GREVAX H5N1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GREVAX H5N1.